Endobronchial Valve (EBV) treatment, like the lung volume reduction surgery is aimed at removing hyperinflated and less functional areas of emphysematous lungs. EBV is less invasive than surgery and has a lower mortality rate. Furthermore, Endobronchial Valve is also much cheaper than surgery. Endobronchial Valve allow expiration of air from the lobe and prevents its re-inflation. In a completely treated lobe, EBV reduces the lobar volume and eventually a full lobar collapse leading to the reduction of lung hyperinflation to improvements in exercise capacity, breathlessness, quality of life and physical activity.
Emphysema is a chronic obstructive pulmonary disorder, which involves damage to the air sacs (alveoli) in the lungs. It is a form of chronic lung disorder which causes difficulty in breathing. The exhalation of airflow slows down due to the over-inflammation of the alveoli. The endobronchial valve closes during the inhalation to stop air from entering the damaged part of the lung. These valves reopen during exhalation to let out the trapped air to reduce pressure. One of the major causes of emphysema is smoking. According to studies, smokers are 6 times more likely to have emphysema than non-smokers.
Important advancements in identifying the treatment responders have been made over the years. Crucial steps in the success of treatment include: a fully occluded lobe, presence of an emphysematous treatment target lobe, and the absence of interlobar collateral ventilation. It is estimated that one billion could die from smoking in this century, majorly in low-to-middle income countries. Smoking is one the leading risks for early death 8 million people died from smoking in 2017. 15% of global deaths are attributed to smoking.
Based on product, the market is bifurcated into Duckbill-shaped and Umbrella-shaped Endobronchial Valves. Based on end-user the endobronchial valves market is segmented into Hospitals, Clinical Research Centers, Ambulatory Surgery Centers and Others.
For a better understanding of the market adoption detailed analysis is conducted for major regions including North America (US, Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, UK, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World.
Some of the major players operating in the market include Pulmonx Corporation (Zephyr), Spiration Inc., MedLung, Novatech and Olympus Corporation. Several M&A’s along with partnerships have been undertaken by these players to boost their presence in different regions.
TABLE OF CONTENTS
1 MARKET INTRODUCTION
1.1. Market Definitions
1.2. Objective of the Study
1.4. Stake Holders
1.5. Currency Used in Report
1.6. Scope of the Endobronchial Valve System Market Study
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Methodology for the Endobronchial Valve System Market
2.1.1. Main Objective of the Endobronchial Valve System Market
3 INDUSTRY PERFORMANCE
4 EXECUTIVE SUMMARY
5 COVID-19 IMPACT
6 MARKET INSIGHTS BY PROCDUCT
6.1. Duckbill-shaped Endobronchial Valves
6.2. Umbrella-shaped Endobronchial Valves
7 MARKET INSIGHTS BY END-USER
7.2. Clinical Research Centers
7.3. Ambulatory Surgery Centers
8 MARKET INSIGHTS BY REGION
8.1. NORTH AMERICA ENDOBRONCHIAL VALVE SYSTEM MARKET
8.1.1. United States of America
8.1.3. Rest of North America
8.2. EUROPE ENDOBRONCHIAL VALVE SYSTEM MARKET
8.2.1. United Kingdom
8.2.6. Rest of Europe
8.3. ASIA-PACIFIC ENDOBRONCHIAL VALVE SYSTEM MARKET
8.3.5. Rest of Asia-Pacific
8.4. REST OF THE WORLD ENDOBRONCHIAL VALVE SYSTEM MARKET
9 LEGAL AND REGULATORY FRAMEWORK
10 DEMAND AND SUPPLY SIDE ANALYSIS
10.1. Demand Side Analysis
10.2. Supply Side Analysis
10.2.1. Top Product Launches
10.2.2. Top Business Partnerships
10.2.3. Top Business Expansions, Investments and Divestitures
10.2.4. Top Merger and Acquisitions
11 VALUE CHAIN ANALYSIS
12 ENDOBRONCHIAL VALVE SYSTEM MARKET TRENDS & INSIGHTS
13 ENDOBRONCHIAL VALVE SYSTEM MARKET DYNAMICS
13.3. Impact Analysis
14 COMPETITIVE SCENARIO
14.1. Endobronchial Valve System Market Share, by Company 2020
15 COMPANY PROFILED
15.1. Pulmonx Corporation (Zephyr)
15.2. Spiration Inc
15.5. Olympus Corporation
16 DISCLAIMER —-
+44 203 500 2763
+1 62 825 80070
Note: The Heraldkeeper News Department was not involved in the creation of this content.
If you have any problem with this press release? Contact the source provider Heraldkeeper.com, you can contact them here.